Semax

What It Is

A synthetic heptapeptide developed in Russia, derived from a fragment of adrenocorticotropic hormone (ACTH 4–10) with an added C-terminal Pro-Gly-Pro sequence to resist enzymatic degradation. Studied across Russian and international literature for its effects on neurotrophic and neurotransmitter systems.

How It Works

Semax is delivered intranasally to the research model

→

Crosses into the central nervous system

→

BDNF and NGF expression are upregulated

→

Cognitive and neuroprotective pathways are studied

What Researchers Study It For

BDNF and NGF expression studies

Cognitive-pathway preclinical research

Cerebral ischemia protection models

Melanocortin-system signaling investigations

Common Research Protocols

In published literature, Semax is administered intranasally in microgram-per-kg doses, with research protocols emphasizing the high bioavailability of nasal delivery for short peptides bypassing first-pass metabolism.

Community Interest Areas

The cognitive-neuroscience research community continues to investigate Semax because it sits at an unusual intersection — derived from an ACTH fragment but stripped of corticotropic activity, while showing measurable effects on neurotrophin expression in animal models. It remains a recurring tool in studies of stroke models, learning paradigms, and stress-resilience pathways.

ACTH(4–10) Stabilized heptapeptide analog with Pro-Gly-Pro tail

Intranasal High-bioavailability nasal route research

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.

What It Is

How It Works

What Researchers Study It For

Common Research Protocols

Community Interest Areas

What Are Peptides?

Are Peptides Safe?